The updated size is slightly smaller than our former traditional tabloid size, but little else has changed.
As you've likely noticed, this issue of Urology Times features a reduced, 9x12-inch publication size. Market research by publishing companies, including Advanstar Communications, the publisher of Urology Times, tells us that readers prefer a tighter, more compact format. We've listened to those requests. And we hope you find that the new size is more streamlined, easier to carry and reference, and more professional in appearance (not to mention more sturdy in the hands of a less-than-gentle U.S. Postal Service). The quarterly peer-reviewed Urology Times Clinical Edition will remain 8½ x 11 inches in size.
It's worth noting that how we define what's "inside" has undergone a significant transformation. A broad array of electronic offerings now complements our print content. Our 360° Network Guide provides a quick snapshot of these online offerings: news and updates, educational materials (including patient handouts and CME articles), podcasts, online tools (including financial calculators and patient forms), and community posts (including a blog by Neal Shore, MD, a Urology Times private practice board member). Each print article that has a tie-in to online content is flagged with a 360° Network icon for easy reference.
I welcome your comments about Urology Times' new size and our expanded multimedia offerings. Your input helps us to continuously improve and deliver the news and information that is most meaningful to you and your practice.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.